BVXV - BiondVax Pharmaceuticals Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
6.66
-0.06 (-0.89%)
At close: 3:46PM EDT
Stock chart is not supported by your current browser
Previous Close6.72
Open6.70
Bid0.00 x 1100
Ask0.00 x 900
Day's Range6.54 - 6.74
52 Week Range4.60 - 10.75
Volume4,498
Avg. Volume10,853
Market Cap43.526M
Beta0.71
PE Ratio (TTM)N/A
EPS (TTM)-1.68
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Research18 days ago

    BVXV: Set to Initiate Phase 3 Clinical Trial of Universal Influenza Vaccine Candidate in 2H18

    BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has received feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).

  • BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update
    PR Newswire24 days ago

    BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update

    NESS ZIONA, Israel , April 30, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal ...

  • ACCESSWIRElast month

    Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US

    Stock Monitor: Dare Bioscience Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on BiondVax Pharma Ltd (NASDAQ: BVXV ) (''BiondVax''). ...

  • BiondVax to Present at Universal Influenza Vaccines Conference
    PR Newswirelast month

    BiondVax to Present at Universal Influenza Vaccines Conference

    NESS ZIONA, Israel , April 12, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal flu vaccine candidate M-001, reported today it will present at the Universal ...

  • PR Newswirelast month

    BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States

    NESS ZIONA, Israel , April 11, 2018 /PRNewswire/ --   BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) reported today the first participant enrollment in the United States in a Phase 2 clinical trial of the ...

  • GlobeNewswire2 months ago

    Recent Analysis Shows Norbord, BiondVax Pharmaceuticals, NXP Semiconductors N.V, Lazard, Canadian Solar, and Sierra Wireless Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • GlobeNewswire2 months ago

    Recent Analysis Shows KB Financial Group, Southern Missouri, Net 1 UEPS Technologies, Financial Engines, Carbonite, and BiondVax Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, March 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate
    PR Newswire2 months ago

    BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate

    NESS ZIONA, Israel, March 13, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (BVXV), developer of the Universal Flu Vaccine candidate M-001, announced today the signing of a Master Service Agreement (MSA) with a contract research organization (CRO) to conduct the first pivotal, clinical efficacy, Phase 3 trial of M-001. BiondVax's pivotal, clinical efficacy, Phase 3 trial is planned to begin later this year, prior to the 2018/19 Northern Hemisphere flu season.

  • BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference
    PR Newswire3 months ago

    BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference

    NESS ZIONA, Israel, Feb. 8, 2018 /PRNewswire/ --BiondVax Pharmaceuticals Ltd. (BVXV), developer of a Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, and the European UNISEC consortium announced today they will co-host the Annual UNISEC Consortium Meeting, which will take place next week in Jerusalem, Israel. Attendees representing the consortium's partners from academia, government, and industry will discuss achievements towards development of a universal influenza vaccine, including the recent successful results of the Phase 2b clinical trial on BiondVax's universal flu vaccine candidate M-001. Also expected to attend will be representatives from the U.S. Department of Health and Human Services (HHS).

  • BiondVax Universal Flu Vaccine Patent Granted in India
    PR Newswire5 months ago

    BiondVax Universal Flu Vaccine Patent Granted in India

    NESS ZIONA, Israel, Jan. 2, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) (BVXV), developer of M-001, the Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, announced today that one of its key patents titled "A Synthetic or Recombinant Influenza Multi-Epitope Polypeptide" has been granted in India. The patent belongs to BiondVax's portfolio family titled "Multimeric Multi-Epitope Influenza Vaccines" and has now been granted in over 30 countries. With a population of over 1.3 billion people, and high population density in some of the major cities, India is an important potential market for BiondVax and a universal flu vaccine may significantly improve public health.

  • BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)
    PR Newswire5 months ago

    BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)

    NESS ZIONA, Israel, Dec. 27, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV) announced today that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) reviewed BiondVax's Phase 3 trial plan, provided advice, and allowed the Company to proceed with the Phase 3 clinical trial plan for M-001, BiondVax's universal flu vaccine candidate. Babecoff continued, "There is a clear need to improve upon current flu vaccine technologies, as noted in the recent New England Journal of Medicine article titled Chasing Seasonal Influenza — The Need for a Universal Influenza Vaccine.[1]  BiondVax's Universal Flu Vaccine candidate is designed to address challenges of current flu vaccines such as mismatches, mutations, and long production lag.

  • Zacks Small Cap Research5 months ago

    BVXV: Planning Continues for M-001 Phase 3 Program …

    BiondVax’s (BVXV) strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has already initiated discussions with the European Medicines Agency (EMA) regarding the trial design. The trial is being conducted in Eastern Europe since there are not recommendations in some of those countries to get the yearly influenza vaccine, thus making it much easier to enroll sufficient numbers of subjects who have not been previously immunized with the yearly influenza vaccine.

  • ACCESSWIRE5 months ago

    Blog Exposure - Synlogic And Ginkgo Bioworks Collaborate to Discover and Develop New Medicines for Neurological and Liver Disorders

    Stock Monitor: BiondVax Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 11, 2017 / Active-Investors issued a free report on Synlogic, Inc. (NASDAQ: SYBX ), which is readily accessible ...

  • BiondVax's CEO Issues Letter to Shareholders
    PR Newswire6 months ago

    BiondVax's CEO Issues Letter to Shareholders

    NESS ZIONA, Israel , Dec. 5, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today released a Letter from the CEO regarding recent activities and plans. "BiondVax has ...

  • PR Newswire6 months ago

    BiondVax Provides Third Quarter 2017 Financial Results and Update

    NESS ZIONA, Israel , Nov. 28, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, ...

  • PR Newswire6 months ago

    BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced the signing of the clinical trial agreement (CTA) for a Phase 2 clinical trial with the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH). The study is titled "A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity, and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Trivalent Influenza Vaccine." It is designed to evaluate the cell mediated immunity directly induced by BiondVax's universal flu vaccine candidate M-001, as well as M-001's priming effect to enhance the immunogenicity of current seasonal influenza vaccines.

  • Zacks Small Cap Research8 months ago

    BVXV: Raises $10 Million to Help Support M-001 Pivotal P3 Program as Standalone Universal Influenza Vaccine

    As expected, the company did not report any revenues during the quarter. The company reported a net loss of $3.5 million for the second quarter of 2017, which was comprised of $0.6 million in R&D expenses and $0.2 million in G&A expenses. On September 19, 2017, the company announced the closing of a public offering of 1.5 million American Depository Shares (ADS) for $6.00 per ADS.

  • PR Newswire8 months ago

    BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced today that it has closed an underwritten public offering of 1,500,000 American Depositary Shares ("ADS"), each ADS representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each), at a price to the public of $6.00 per ADS. In connection with the public offering, the underwriters exercised in full their over-allotment option to purchase an additional 166,667 shares of common stock at the public offering price, less the underwriting discount. As a result, the total public offering size was 1,666,667 shares, and the gross proceeds from the public offering were $10 million, before deducting underwriting discounts and offering expenses.

  • PR Newswire8 months ago

    BiondVax Announces Pricing of Public Offering of American Depositary Shares

    NESS ZIONA, Israel, Sept. 13, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced today that it has priced an underwritten public offering of 1,500,000 American Depositary Shares ("ADS"), each ADS representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each), at a price to the public of $6.00 per ADS. BiondVax Pharmaceuticals has granted the underwriter a 45-day option to purchase up to 166,667 additional ADS. The ADSs described above will be issued pursuant to a registration statement on Form F-3 previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on December 15, 2016.

  • PR Newswire8 months ago

    BiondVax Announces Public Offering of American Depositary Shares

    BiondVax Pharmaceuticals Ltd. (BVXV) (BVXV.TA), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced that it intends to offer for sale its American Depositary Shares ("ADS"), each representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each). All of the ADSs in the offering are being offered by BiondVax. The offering is subject to market conditions and there can be no assurance as to whether the offering may be completed, or as to the actual size or terms of the offering.

  • Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)?
    Simply Wall St.8 months ago

    Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)?

    BiondVax Pharmaceuticals Ltd (NASDAQ:BVXV), a pharmaceuticals, biotechnology and life sciences company based in Israel, See our latest analysis for BVXV What’s the opportunity in BVXV? Great news for investors –Read More...

  • ACCESSWIRE8 months ago

    Featured Company News - Oncobiologics Announces Partnership with GMS Tenshi Holdings; Set to Accelerate the Commercialization of Biosimilar Candidates

    Research Desk Line-up: BiondVax Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...

  • PR Newswire9 months ago

    Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), developer of the universal flu vaccine candidate M-001, today announced that its Board of Directors has decided to voluntarily delist from the Tel Aviv Stock Exchange (TASE), while maintaining a continued listing on NASDAQ. Following the European Investment Bank (EIB)'s significant €20 million funding agreement[1], and as BiondVax progresses towards Phase 3 clinical trials[2] and construction of its commercial mid-size manufacturing facility[3], the Board of Directors decided that BiondVax will focus its efforts on the international scene.

  • PR Newswire9 months ago

    BiondVax Provides Second Quarter 2017 Financial Results and Update

    NESS ZIONA, Israel , Aug. 31, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, ...

  • PR Newswire9 months ago

    BiondVax Receives Additional Grant Funding

    Israel Innovation Authority Approves Additional Budget towards M-001 Flu Vaccine Development NESS ZIONA, Israel , August 14, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) (TASE: BVXV) ...